Kellner Capital adds Baxalta Inc (BXLT) to its portfolio

Baxalta Inc (BXLT) : Kellner Capital added new position in Baxalta Inc during the most recent quarter end. The investment management firm now holds 244,700 shares of Baxalta Inc which is valued at $10.4 Million , the company said in a statement filed on May 12, 2016 with the SEC.Baxalta Inc makes up approximately 7.28% of Kellner Capital’s portfolio.

Other Hedge Funds, Including , Ubs Asset Management Americas Inc reduced its stake in BXLT by selling 934,508 shares or 32.06% in the most recent quarter. The Hedge Fund company now holds 1,980,722 shares of BXLT which is valued at $84 Million. Baxalta Inc makes up approx 0.10% of Ubs Asset Management Americas Inc’s portfolio.Highlander Capital Management reduced its stake in BXLT by selling 700 shares or 20.9% in the most recent quarter. The Hedge Fund company now holds 2,650 shares of BXLT which is valued at $112,334. Baxalta Inc makes up approx 0.12% of Highlander Capital Management’s portfolio.Commonwealth Of Pennsylvania Public School Empls Retrmt Sys boosted its stake in BXLT in the latest quarter, The investment management firm added 15,091 additional shares and now holds a total of 50,554 shares of Baxalta Inc which is valued at $2.1 Million. Baxalta Inc makes up approx 0.05% of Commonwealth Of Pennsylvania Public School Empls Retrmt Sys’s portfolio.Choate Investment Advisors boosted its stake in BXLT in the latest quarter, The investment management firm added 19,476 additional shares and now holds a total of 19,615 shares of Baxalta Inc which is valued at $807,550. Baxalta Inc makes up approx 0.06% of Choate Investment Advisors’s portfolio.

Baxalta Inc opened for trading at $44.21 and hit $44.65 on the upside on Friday, eventually ending the session at $44.43, with a gain of 1.62% or 0.71 points. The heightened volatility saw the trading volume jump to 1,35,80,226 shares. Company has a market cap of $30,369,682 M.

On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.

Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

Baxalta Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxalta Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.